Halozyme Therapeutics (HALO) Current Deferred Revenue (2010 - 2023)

Halozyme Therapeutics (HALO) has 14 years of Current Deferred Revenue data on file, last reported at $2.9 million in Q3 2023.

• Current Deferred Revenue for Q3 2023 came in at $2.9 million, down 54.82% year-over-year; the trailing twelve-month figure through Sep 2023 was $2.9 million (down 54.82% YoY), and the FY2022 annual result was $3.2 million, up 85.91% from the prior year.
• Current Deferred Revenue grew to $2.9 million in Q3 2023 per HALO's latest filing, from $842000.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $6.9 million in Q2 2022 and troughed at $842000.0 in Q2 2023.
• A 5-year average of $3.6 million and a median of $3.5 million in 2019 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2019 and 2022: Current Deferred Revenue plunged 89.85% in 2019, then surged 450.92% in 2022.
• A 5-year view of Current Deferred Revenue shows it stood at $5.3 million in 2019, then tumbled by 66.8% to $1.7 million in 2020, then changed by 0.0% to $1.7 million in 2021, then soared by 85.91% to $3.2 million in 2022, then retreated by 10.66% to $2.9 million in 2023.
• Business Quant data shows HALO's Current Deferred Revenue at $2.9 million in Q3 2023, $842000.0 in Q2 2023, and $5.5 million in Q1 2023.